The Scotts Miracle-Gro Company logo SMG - The Scotts Miracle-Gro Company

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY
0
BUY 9
HOLD 7
SELL 1
STRONG
SELL
0
| PRICE TARGET: $77.25 DETAILS
HIGH: $79.00
LOW: $75.00
MEDIAN: $77.50
CONSENSUS: $77.25
UPSIDE: 23.38%
AlphaVal

AlphaVal

Deterministic, archetype-aware fair value

Cyclical & Capital-Intensive 80% confidence

Primary model: Normalized Earnings × Cycle Multiple

Valuation Signal Overvalued Strong
Trading 227.6% above fair value
Current Price $62.61
Bear Case $14.08 77.5% downside ($14.08 - $62.61) / $62.61 = -77.5% $2.01 × 7x
Fair Value $19.11 69.5% downside ($19.11 - $62.61) / $62.61 = -69.5% $2.01 × 10x
Bull Case $24.14 61.4% downside ($24.14 - $62.61) / $62.61 = -61.4% $2.01 × 12x

Adjust Assumptions

9.5x
2.01$

Key Value Driver

Through-cycle normalized EPS ($2.01)

Implied Market Multiple 31.1x

Plain-Language Summary

Using 7-year normalized EPS of $2.01 at a 10x cycle multiple, the base-case value is $19.11 per share.

Analyst Consensus (External Reference)

Never blended into the bear/base/bull estimates above -- shown only as an outside comparison.

Average Target (17 analysts) $77.25
Analyst Range $75.00 – $79.00
Divergence from AlphaVal 75%

Warnings

This company has a built-in lending arm whose debt is mixed in with the main business. We capped the debt adjustment to avoid overstating what the core business owes.
Wall Street's average price target is $77.25 (from 17 analysts). Our estimate is 75% below the consensus -- consider that gap carefully.

Key Risks

  • Standard 10-year DCF produces unreliable terminal values for cyclicals
  • 'Cheap' P/E at cycle peak is the most common value trap — normalize first
  • Captive finance subsidiaries have different risk profiles from manufacturing